310 related articles for article (PubMed ID: 28366492)
1. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
Takei K; Nakagawa Y; Wang Y; Han SI; Satoh A; Sekiya M; Matsuzaka T; Shimano H
J Pharmacol Sci; 2017 Apr; 133(4):214-222. PubMed ID: 28366492
[TBL] [Abstract][Full Text] [Related]
2. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
[TBL] [Abstract][Full Text] [Related]
3. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
[TBL] [Abstract][Full Text] [Related]
4. Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.
Dong T; Lyu J; Imachi H; Kobayashi T; Fukunaga K; Sato S; Ibata T; Yoshimoto T; Yonezaki K; Iwama H; Zhang G; Murao K
Eur J Pharmacol; 2018 Nov; 838():78-84. PubMed ID: 30201376
[TBL] [Abstract][Full Text] [Related]
5. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
6. Fucoidan A2 from the Brown Seaweed Ascophyllum nodosum Lowers Lipid by Improving Reverse Cholesterol Transport in C57BL/6J Mice Fed a High-Fat Diet.
Yang Z; Liu G; Wang Y; Yin J; Wang J; Xia B; Li T; Yang X; Hou P; Hu S; Song W; Guo S
J Agric Food Chem; 2019 May; 67(20):5782-5791. PubMed ID: 31055921
[TBL] [Abstract][Full Text] [Related]
7. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
8. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
[TBL] [Abstract][Full Text] [Related]
9. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
[TBL] [Abstract][Full Text] [Related]
10. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
[TBL] [Abstract][Full Text] [Related]
11. The fucoidan A3 from the seaweed Ascophyllum nodosum enhances RCT-related genes expression in hyperlipidemic C57BL/6J mice.
Yang Z; Yin J; Wang Y; Wang J; Xia B; Li T; Yang X; Hu S; Ji C; Guo S
Int J Biol Macromol; 2019 Aug; 134():759-769. PubMed ID: 31100394
[TBL] [Abstract][Full Text] [Related]
12. Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.
Yamamoto H; Yamanashi Y; Takada T; Mu S; Tanaka Y; Komine T; Suzuki H
Mol Pharmacol; 2019 Jul; 96(1):47-55. PubMed ID: 31064810
[TBL] [Abstract][Full Text] [Related]
13. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
Wang Y; Tang W; Yang P; Shin H; Li Q
Biochem Biophys Res Commun; 2018 May; 499(3):626-633. PubMed ID: 29601818
[TBL] [Abstract][Full Text] [Related]
14. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
15. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
Fruchart JC
Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
17. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
[TBL] [Abstract][Full Text] [Related]
19. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
20. Pemafibrate: First Global Approval.
Blair HA
Drugs; 2017 Oct; 77(16):1805-1810. PubMed ID: 28929345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
